Live Biotherapeutic Products (LBPs), as defined by the U.S. Food and Drug Administration, are biological products containing live microorganisms intended for the prevention, treatment, or cure of human disease. Distinct from vaccines, their therapeutic effects derive from the biological activity of the living organism itself, including intrinsic functions and, where applicable, metabolites produced in situ. LBPs may originate from human or environmental sources or be rationally designed and are developed, manufactured, and regulated as drugs or biologics for clinical use. Once confined to experimental research, LBPs are now transitioning into approved therapeutics. The approvals of Rebyota and Vowst for recurrent Clostridioides difficile infection mark a pivotal milestone, establishing LBPs as a new therapeutic class. Although the global LBP market currently remains in the tens to low hundreds of millions of U.S. dollars, it is projected to grow at compound annual rates of approximately 13-25 %, with estimates ranging from USD 400 million to 2.6 billion by 2030-2034. Emerging recombinant LBPs further expand this paradigm, enabling enzymatic and peptide drug synthesis and precision delivery platforms. In parallel, regulatory frameworks are evolving, with both the FDA and EMA defining pathways that emphasize quality control, donor sourcing, potency, biosafety, and environmental risk assessment, particularly for genetically modified organisms. Commercial opportunities are driven by unmet needs in gastrointestinal, immune, and metabolic disorders, with potential extension into oncology. Progress, however, is tempered by manufacturing complexity, regulatory burden, reimbursement challenges, public perception, and incomplete mechanistic understanding. Despite these hurdles, the future is compelling, marked by expanding indications, engineered strains, standardized consortia, scalable manufacturing, regulatory harmonization, and accelerating investment.
Live Biotherapeutic Products (LBPs) represent a promising and rapidly advancing class of therapeutics that harness live microorganisms to prevent, treat, or manage a wide spectrum of health disorders. Distinct from traditional probiotics, prebiotics, and synbiotics, LBPs are rigorously developed and regulated as medicinal products with defined compositions, mechanisms of action, and clinical indications. Looking ahead, the therapeutic potential of LBPs is expanding well beyond gastrointestinal disorders, with promising applications in areas such as metabolic, neurological, and immune-mediated diseases. Their integration into precision medicine frameworks holds significant promise for shaping the future of public health. This chapter provides an overview of currently available LBPs, their mode of actions, clinical applications, and the regulatory frameworks that distinguish them from other microbial-based therapies. It also highlights the growing diversity of LBPs from single-strain products to engineered microbial communities and natural formulations, emphasizing their unique clinical value and increasingly advanced mechanisms of action. The clinical development of LBPs faces key challenges, including strain selection, complex manufacturing, viability issue and safety concerns in vulnerable populations with comorbidities, and navigating evolving regulatory frameworks. Advances in synthetic biology, CRISPR genome editing, and multi-omics are transforming LBP design, enabling more precise and personalized therapies. The evolving LBP landscape with key industry players, clinical trials, and strategic partnerships offers critical insights into the innovation and commercialization driving this dynamic field.
Single-cell (SC) and spatial transcriptomics (ST) have transformed molecular biology by allowing high-resolution profiling of gene expression in individual cells and tissues. These approaches reveal cellular diversity, developmental pathways, and disease processes, yet the resulting datasets are large and complex. Artificial intelligence (AI) especially machine learning (ML) and deep learning (DL) now plays a central role in managing this complexity by automating preprocessing, reducing dimensionality, and supporting cell classification and clustering. AI methods also help integrate multi-omics layers, identify spatial patterns, and infer cellular trajectories, strengthening our ability to interpret biological systems. This chapter examines how AI advances the analysis of single-cell and spatial transcriptomics, focusing on methods such as convolutional neural networks (CNN), graph neural networks, (GNN) and variational autoencoders (VAE). It highlights applications in cancer biology, immunology, and neuroscience, including the prediction of cellular behavior and disease mechanisms relevant to personalized medicine. Remaining challenges include scalability, interpretability, and consistent data standards. The chapter concludes with future directions aimed at improving model transparency, enhancing multi-modal integration, and addressing ethical issues in clinical use, offering researchers a concise guide to applying AI for deeper insights into cellular data.
Artificial intelligence (AI) is rapidly growing in how researchers study biomolecular structures of proteins and nucleic acids. The use of traditional methods like X-ray crystallography and electron microscopy resolves structural details but these are time-consuming and costly. AI, especially deep learning models, e.g., AlphaFold2 and RoseTTAFold, enables scientists to predict accurate 3D structures quickly from sequence data, opening new ways in understanding molecular functions and drug discovery. This chapter explains key concepts of machine learning and its architectures used in structural biology, including convolutional (CNN) and graph neural networks (GNN), recurrent neural networks (RNN), and transformers. It provides details on how AI helps not only in predicting 3D structures but also in identifying functional sites and interactions, aiding enzyme engineering and therapeutic design towards targets. The experimental data and integration of AI are also discussed, explaining how these techniques complement each other to improve structural determinants. The Challenges faced, like interpretability of the model, data quality, and ethical concerns, are highlighted, along with accessibility for researchers. Overall, this chapter provides a basic overview of the use of AI in biomolecular structural analysis and is designed to equip beginners with the primary knowledge to explore this exciting interdisciplinary field.
Once restricted to cellular boundaries, cell-free expression has advanced to the forefront of contemporary biotechnology, heralding a novel paradigm in protein and enzyme biosynthesis. Cell-free expression system (CFES) offers an exquisite platform for production of these biomolecules in an open and controlled environment, liberated from the constraints of cellular regulations. The CFES facilitates precise manipulation of expression dynamics, thereby enabling the synthesis of proteins that are otherwise challenging to express in conventional hosts. Initially conceived as a pivotal tool for deciphering the genetic code, this technology has evolved into a sophisticated and versatile system for biosynthesis of proteins and enzymes, empowering researchers with unprecedented control over the molecular machinery of life. Biosynthesis of toxic proteins and complex enzymes in a flexible and highly regulated cell-free environment offers a panoply of applications in diagnostics, therapeutics, biomanufacturing and synthetic biology. From rudimentary extract-based systems to highly advanced and well-developed systems such as protein synthesis using recombinant elements (PURE), cell-free expression has profoundly reshaped the scientific landscape in ways that were previously unimaginable. Since the time of their inception, CFESs have elegantly exemplified the fusion of engineering and biological insights, thereby advancing the field from a technical curiosity to a treasure trove of possibilities. This chapter traces the journey of cell-free expression of proteins and enzymes followed by an extensive review of different types and formats of CFESs. Finally, the chapter ends by providing brief description of various applications, challenges and revolutionary promises that the cell-free systems behold for future.
Fecal microbiota transplantation (FMT) is a biologically coherent strategy to modulate the gut-liver axis by restoring ecosystem structure and function. This chapter synthesizes current evidence and practice of FMT in various liver disease conditions. In cirrhosis with recurrent hepatic encephalopathy (HE), randomized trials demonstrate adjunctive benefits of FMT, reducing recurrence and hospitalizations as well as improving cognition, with route flexibility (lower-GI infusions or oral capsules) and emerging microbiome predictors of response. In severe alcohol-associated hepatitis and ACLF, early single-center trials suggest fewer infections and short-term survival gains, warranting confirmation in multicenter, blinded studies for further outcomes. For MASLD/MASH, FMT consistently shifts intestinal permeability, bile-acid signatures, and hepatic transcriptomics, although it has not reliably improved MRI-PDFF or insulin resistance in unselected cohorts; future success likely requires phenotype enrichment and function-matched donors or defined consortia. Data in chronic hepatitis B remain exploratory, positioning FMT, if at all, as an adjunct to antivirals. Methods are standardized around rigorous donor screening, controlled manufacturing, indication-specific endpoints, and strain-resolved engraftment analytics linking mechanism to outcome. Refractory Clostridium difficile is the only FDA-approved indication of FMT. Use of FMT in hepatology use should remain protocolled and regulated. Priorities include precision donor matching, next-generation consortia, platform trials, and long-term safety registries.
Single-particle cryo-electron microscopy (cryo-EM) has rapidly evolved from largely manual, stepwise workflows to AI-assisted, increasingly automated protein structure determination pipelines. This chapter presents an end-to-end view on our deep learning-based AI tools that address three major stages of cryo-EM data analysis: protein particle picking, density map enhancement, and atomic structural model building. First, we introduce two of our AI-based particle pickers: CryoTransformer, a transformer-residual architecture trained on the large-scale CryoPPP dataset, and CryoSegNet, which couples a cryo-EM-specialized attention-gated U-Net with SAM to segment particles across diverse proteins and imaging conditions. Together, they deliver high precision-recall performance and improve downstream 3D reconstructions, outperforming widely used pickers on independent benchmarks. Second, we describe CryoTEN, a 3D UNETR++-style transformer to enhance cryo-EM density maps. On a 150-map test set, CryoTEN robustly improves local interpretability and downstream protein structure modeling while running>10× faster than other deep learning methods. Third, we present our two atomic protein model building frameworks: Cryo2Struct and MICA. Cryo2Struct is a fully automated de novo modeling framework that identifies atoms and residue types from density maps alone via a 3D transformer and assembles them into chains with a Hidden Markov Model, producing more complete and accurate models than other ab initio tools. MICA, a multimodal framework that integrates cryo-EM density maps with AlphaFold3 structure predictions at both input and output levels to further refine model accuracy and completeness, achieving near-experimental TM-scores on recently released high resolution density maps. Finally, we conclude by outlining open challenges and potential future directions in cryo-EM data analysis.
Multi-omics research has transformed our ability to study biological systems by capturing information across multiple molecular layers, including genomics, transcriptomics, epigenomics, proteomics, metabolomics, and microbiomics. Each omics dimension provides a unique perspective on cellular and organismal function, yet single-omics approaches often fail to capture the full complexity of health and disease. Integrating diverse omics datasets offers a systems-level view that is essential for advancing precision medicine, addressing disease heterogeneity, and uncovering mechanisms of pathogenesis. The increasing availability of high-dimensional, heterogeneous data demands robust computational and AI-driven approaches. Methods ranging from traditional statistical techniques to advanced deep learning and network-based models enable the integration, analysis, and interpretation of multi-omics data. These approaches have already demonstrated significant impact in cancer, cardiovascular and metabolic disorders, neurodegenerative diseases, infectious diseases, and rare genetic conditions. Translational applications include biomarker discovery, patient stratification, therapy optimization, drug repurposing, and clinical decision support. Despite these advances, challenges remain in data standardization, scalability, interpretability, and ethical use of genomic information. Future directions emphasize explainable AI, regulatory frameworks, and integration with digital health records to bridge research insights with clinical practice. Overall, AI-powered multi-omics integration will shape the future of biomedical research and precision healthcare.
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, with standard pharmacological interventions often failing to fully address their complex pathophysiology. Recent advances in microbial medicine highlight the human gut microbiome as a critical regulator of cardiovascular health. Gut microbial metabolites such as short-chain fatty acids (SCFAs), trimethylamine-N-oxide (TMAO), and indole derivatives play pivotal roles in modulating inflammation, lipid metabolism, immune function, and vascular homeostasis. Dysbiosis, or microbial imbalance, has been strongly associated with atherosclerosis, hypertension, and heart failure. Consequently, therapies targeting the gut microbiota including probiotics, prebiotics, synbiotics, and postbiotics have emerged as promising adjuncts in CVD prevention and treatment. Moreover, fecal microbiota transplantation (FMT) and synthetic biology approaches using engineered microbes offer novel strategies to restore microbial balance and deliver therapeutic molecules. Dietary interventions, particularly Mediterranean and fiber-rich diets, further support cardiovascular health through microbiota modulation. While preclinical and clinical studies underscore the potential of microbiome-based interventions, challenges related to strain specificity, delivery systems, and regulatory frameworks remain. Nonetheless, integrating microbial medicine into cardiovascular care represents a transformative shift toward precision, holistic, and personalized treatment paradigms. This chapter explores these cutting-edge therapeutic interventions and their implications for reshaping the future landscape of cardiovascular disease management.
Live biotherapeutics which are live microorganisms with clinically validated therapeutic benefits are rapidly emerging as innovative interventions for a broad spectrum of health disorders. The human reproductive tract, particularly the female vagina is home to specific microbial community that play a vital role in maintaining mucosal immunity, preventing pathogen colonization and supporting successful pregnancy outcomes. Disruption to this microbial balance have been strongly associated with conditions such as bacterial vaginosis (BV), sexually transmitted infections (STI), infertility and pregnancy complications such as pre-term birth. Given the adverse effects of conventional pharmaceutical treatments, microbiome based therapeutic strategies are gaining increasing popularity as safer and more sustainable alternatives. Recent advancements in synthetic biology, genetic engineering and microbiome science have enabled the development of next generation live biotherapeutics that go beyond traditional probiotics which are intended for only maintaining general health. This chapter explores the human reproductive tract microbiome as a novel and promising source of live biotherapeutics candidates. We examine the composition and functional potential of microbial communities within the reproductive tract, the mechanisms by which they interact with the host, and the emerging evidence supporting the therapeutic applications of vaginally isolated microorganisms. Additionally, we highlight recent advancements in research focused on reproductive tract microbiome, strategies of mining live biotherapeutic product (LBP) candidates, and enlist few potential vaginal origin-LBPs and their associated studies. In addition, this chapter briefly introduces emerging strategies aimed at addressing reproductive health challenges such as vaginal microbiome transplantation (VMT) as innovative tool for addressing persistent challenges in reproductive health.
Liver diseases, including hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), non-alcoholic fatty liver disease (NAFLD), and cirrhosis, account for over 2 million deaths each year worldwide. Due to their intricate etiology, which encompasses genetic, epigenetic, environmental, and metabolic factors cause late diagnosis. Advances in multi-omics techniques generate huge and complex data including genomics, epigenomics, transcriptomics, proteomics, and metabolomics which revolutionize the understanding of biological systems at different layers of complexity. Furthermore, advances in integrating multi-omics data using artificial intelligence(AI) helping in identifying common factors dysregulated at different layers in biological systems to identify the disease etiology, diseases subtyping, diagnosis and prognosis modeling. This chapter discusses the common omics data and application of AI in the integration of multi-omics data for deep investigation of liver diseases to enhance the understanding of disease mechanisms, identify biomarkers, and discover therapeutic targets for the progression of precision medicine. Furthermore, we discuss about persistent challenges in integrating heterogeneous omics datasets including variations in data format, scale, and AI model interpretability. The incorporation of AI-driven multi-omics approach in clinical hepatology will support more accurate and early diagnosis, disease subtyping, and better treatment planning for precision medicine.
The human gut microbiota is complex environment of diverse microbes that constitutes a key factor in health, immune responses, balance between the microbial community, metabolism, and prevention of diseases. Live biotherapeutic products (LBPs) are engineered live microorganisms that are being used to treat different diseases. LBPs have emerged as promising therapy for the treatment of different human diseases, which include metabolic disorders, pathogenic infections, inflammatory bowel disease (IBD), and cancer overcoming the traditional use of probiotics. Current progress in synthetic biology and genetic engineering have enabled the precise modifications of microbes, which leads to the targeted modulation of interactions with host-microbiome, disease pathways, and immune responses. This chapter highlights the principle of LBPs, interaction between host and its immune response, delivery mechanism and strategy of colonization and applications of LBPs. Key role of synthetic biology in development of LBPs is also discussed. The application of LBPs into clinical use leads to the introduction of safety and regulatory considerations. The delivery of LBPs can be regulated by introducing the biocontainment strategy into the microbes. Looking forward, synergistic engineering methods, personalized microbial consortia, computational biology tools for design of genetic circuits may serve as the foundation for further improvement in the LBPs with the future potential.
Cell-free synthetic biology is a powerful technology that is gaining increasing popularity due to its ability to perform complex biochemical reactions in a well-controlled environment, isolated from the intricacies of living cells. Although it has demonstrated significant success in genetic part characterization and high-throughput protein production without the constraints of cellular membranes, cell-free systems still face several challenges. These include the limited volume available for transcription-translation machinery, the difficulty in standardizing cell lysis procedures, and the variability in cell extract performance across different laboratories. Microfluidic technology has become a powerful tool to address these challenges by supporting the miniaturization and automation of complex, multi-step workflows. Integrating cell-free gene and protein synthesis with microfluidic platforms has redefined bioprocessing, making it more compact and accessible. This synergy has unlocked a wide range of applications across diverse areas of synthetic biology in recent years. This book chapter reviews microfluidic-based methods for synthetic biology in cell-free environments. It highlights the fundamental principles of both cell-free systems and microfluidic technologies, and presents various examples of their integration. The chapter proposes this convergence as a pioneering approach to developing innovative platforms for synthetic biology, with potential applications in biomedical, therapeutic, diagnostic, and environmental contexts.
Live biotherapeutic (LBP) is defined by the FDA as a biological product that: (1) contains live organisms, such as bacteria; (2) applies to the prevention, treatment, or cure of a disease or condition of human beings; and (3) is not a vaccine. Progress in microbiome science and the limitations of antibiotics have necessitated the use of LBPs to complement or replace conventional therapies across multiple medical disciplines. The most important advancement is in the infectious disease domain, where fecal microbiota transplantation validated ecological restoration for recurrent Clostridioides difficile infection and paved the way for the first approved LBPs (REBYOTA® and VOWST™/SER-109). Constructing rational microbial consortia and strain-level strategies aim to induce commensal resilience and prevent the establishment of multidrug-resistant organisms. In oncology, gut microbial composition modulates response to immune checkpoint inhibitors. So, defined microbial consortia and engineered E. coli Nissle are being developed to enhance antitumor immunity and localize payloads. Early studies in animals and humans also support the application of this approach in metabolic disease, allergy, and oral health. Translation from benchside to bedside, however, is fraught with hurdles-variable patient response, manufacturing consistency, safety standards, cost, and ethics-exacerbated by heterogeneous global regulations, underscoring the need for harmonization. Precision microbial consortia, programmable "living medicines," and biohybrid formulations could extend LBPs into broader indications and global health, shifting practice toward an ecological model of therapeutics.
The COVID-19 pandemic has led to an unprecedented increase in the volume of biological data generation, demonstrating the importance of developing an integrative and intelligent analytical framework. In the last few years, advancements in the artificial intelligence (AI) approaches have completely transformed the biological research landscape. Researchers have integrated the AI approaches with the multi-omics data generated from the COVID-19 patients to have a systems-level understanding of underlying disease mechanisms, predicting new variants and their spread rate, disease severity, immune response, and therapeutic opportunities. In this chapter, we have explored the utility of AI on multi-omics data. We started with an introduction to different kinds of omics data, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Next, we elaborated on what AI is and discussed its types, which include conventional machine learning methods (supervised and unsupervised), deep learning methods (autoencoders and convolutional neural networks), and network-based methods (graph neural networks, network propagation, and knowledge graphs). Next, we discussed different types of integration methods (early, intermediate, and late) used for integrating AI and multi-omics data. Moving ahead, we mentioned several applications of AI, such as biomarker discovery, host-pathogen interaction, drug repurposing, and predicting long COVID. Lastly, we mentioned several important projects and consortia and discussed several important case studies highlighting the usefulness of integrating AI with multi-omics data for personalized medicine.
The human gut is home to trillions of microbial lineages, which collectively along with their genomic content form the human microbiome. This community of microbes is crucial to maintaining our health. Imbalance in this community, a state referred to as 'Dysbiosis', has been linked to many diseases. A large domain of research in the human microbiome thus focuses on identifying and administering microbes to restore this imbalance and potentially ameliorate diseases linked to the gut microbiome. These 'microbial medicines', known as live biotherapeutics, are basically living organisms, such as novel types of probiotics or specifically designed groups of bacteria to enhance health. A significant challenge in this context is discovering the right set of microbes. Variability in the baseline gut microbiome even across normal individuals based on demographic factors and context-dependent behavior of specific microbes and strain-specific variations are amongst the various factors that make the microbiome highly individual-specific, resulting in highly personalized responses to different therapeutics. In this, advanced artificial intelligence (AI) derived tools like, Machine Learning (ML) and Deep Learning (DL), can potentially provide major breakthroughs, by facilitating complex analysis of massive amount of microbiome and host OMICs. In this chapter, we discuss ways in which AI can be leveraged to identify patterns "signatures", in microbiome data can facilitate microbiome-derived diagnostics and therapeutics. Using examples, we explore how AI-based models can also look at the complex interactions between microbes and our bodies to discover new, promising bacteria that could be turned into "Live Biotherapeutic Products" (LBPs). This chapter will cover the primary ways of how AI is being utilized, the challenges we still face (such as the need for improved data), and the promising future of using AI to develop a new generation of microbiome-based medicines.
Artificial intelligence (AI) has been introduced to meet the demand for more precise predictions of cancer patient survival by simultaneously interpreting multiple types of input data. These data can originate from a broad spectrum of modalities, where a modality refers to one of several distinct forms in which data can be represented or observed. Using AI, researchers have investigated how to model the interactions among different data modalities as a promising approach to multimodal fusion in cancer prognosis. The goal is to build models capable of reliably handling and integrating these heterogeneous data sources to improve the accuracy and interpretability of patient outcome predictions. Nonetheless, current integration techniques encounter two major obstacles that must be overcome before survival prediction can be carried out: data alignment and data fusion. This chapter surveys existing alignment methods and fusion strategies within a pipeline designed to predict cancer survival. The chapter begins by describing the search strategy followed to identify the relevant literature to be analyzed here. Then, multimodal machine learning is introduced with the three key data types investigated in this study. we review 31 recent multimodal studies related to alignment and fusion using deep learning, covering the period from 2015 to 2025. Among these, 18 studies focus on alignment techniques followed by fusion strategies, while another 13 investigate fusion strategies independently of alignment. This chapter illustrates how synchronizing the data modalities before applying fusion can improve both the performance and the interpretability of the models. The synthesis of these studies uncovers methodological challenges and suggests future directions to develop more effective and clinically relevant AI-based survival prediction frameworks.
Early diagnosis of disease is essential for timely intervention and improved clinical outcomes. Metabolomics offers a powerful approach to predict early clinical events such as disease onset by detecting subtle metabolic changes before clinical symptoms appear. Through real-time metabolic profiling, it provides unique insights into disease initiation, progression, and the underlying pathophysiological mechanisms. This makes metabolomics particularly valuable for identifying early biomarkers in complex and devastating conditions, including various cancers, diabetes and its complications, as well as disorders affecting the brain, heart, liver, kidneys and other essential organs. However, the inherently high-dimensional and complex nature of metabolomics data poses significant analytical challenges particularly when aiming to harness its full potential for predictive and personalized medicine. Extracting meaningful insights from thousands of metabolites across diverse biological contexts requires advanced computational strategies capable of managing data heterogeneity, noise, and non-linear relationships. In this chapter, we present in-depth overview of how Artificial Intelligence (AI)-particularly, machine learning (ML) and deep learning (DL) approaches-has been integrated into metabolomics workflows to overcome these limitations. We discuss both technical and conceptual frameworks essential for state-of-the-art disease prediction, illustrated through recent case studies and methodological advances.
Poxvirus morphogenesis involves extensive cellular membrane remodeling and assembly intermediates that have remained difficult to resolve at the molecular level. Progress in cryo-electron microscopy has been pivotal in characterization of immature poxvirus assembly by enabling direct visualization of scaffold architecture across scales. Structural analyses of in vitro assemblies revealed that the scaffold protein of vaccinia virus D13 forms a curved, honeycomb lattice through specific intertrimer interactions, structural features that promote spherical geometry. Cryo-electron tomography extended this understanding to a cellular context by resolving lattice organization and scaffold removal during maturation, and by revealing the emergence of an internal palisade layer that reshapes the condensing core. Together, these studies indicate that scaffold-mediated curvature, membrane coupling, and sequential lattice deployment define virion size and final architecture. Continued convergence of in vitro and in situ cryo-EM with correlative and time-resolved methods promises deeper understanding of transient intermediates and may guide strategies that target assembly pathways for antiviral intervention.
AI and genomics are revolutionizing precision medicine by using machine learning (ML) to analyze large-scale next-generation sequencing (NGS) data, identifying genetic mutations and biomarkers for personalized therapies. In practice, this accelerates drug discovery and enhances variant detection, while in cancer genomics, AI enables early detection via liquid biopsies and refines treatment by integrating multi-omics data to improve therapeutic precision. However, challenges such as data biases in underrepresented populations, limited model interpretability, and ethical concerns regarding privacy and algorithmic inequity hinder clinical adoption and demand robust governance. Efforts to diversify datasets also face standardization hurdles, although explainable AI and federated learning provide promising solutions for improving transparency and privacy. In this chapter, we discuss the role of AI in advancing genomics from diagnostics to novel therapies and emphasize the need for equitable frameworks to ensure responsible implementation, thereby paving the way for breakthroughs in personalized medicine.